Reviews: 2019 Medicinal Chemistry Reviews

Ref. n°: REV2019

Volume : 54
Editor-In-Chief : Joanne J. Bronson

Medicinal Chemistry Reviews is an outstanding 680 page volume providing timely and critical reviews of important topics in medicinal chemistry. It is provided free of charge to MEDI members in electronic format. Members can also order a print copy, for the cost of printing, shipping and handling

Table of contents

Chapter 1A Love of Chemistry and My Career in Drug Discovery Research.
Bruce E. Maryanoff
Chapter 2Small-Molecule Approaches for the Treatment of Sickle Cell Disease.
Zhe Li, Mira Patel, Donna Oksenberg, Brian Metcalf
Chapter 3New Progress in Protease-Activated Receptor 1 and 4 (Par-1 and Par-4) Antagonists as Antiplatelet Therapy for Treatment Cardiovascular Disease.
Xiaojun Zhang
Chapter 4Recent Advances in the Development of Small-Molecule Inhibitors for Idiopathic Pulmonary Fibrosis (IPF).
Katerina Leftheris, Yajun Zheng, Timothy D. Machajewski
Chapter 5Recent Advances in the Discovery and Development of Interleukin Receptor Associated Kinase 4 (IRAK4) Inhibitors.
Jeromy Cottell, Nathan E. Wright, Matthew Warr, James G. Taylor
Chapter 6Untangling Perception and Reality: Small-Molecule TNF-α Inhibitors.
Jeremy J. Edmunds
Chapter 7IDH Inhibitors for the Treatment of IDH-Mutated Cancer.
Lenny Dang, Brandon Nicolay, Zenon Konteatis
Chapter 8Recent Advances in DHODH Inhibition for Acute Myeloid Leukemia.
Scott D. Kuduk, Justin S. Cisar, E. Christine Pietsch
Chapter 9STING Agonists for Immuno-Oncology.
Thorsten Oost, Christian A. Kuttruff, Herbert Nar
Chapter 10The Discovery of Manogepix/Fosmanogepix and Other Gwt1 Inhibitors for the Treatment of Invasive Fungal Infections.
Jonathan A. Covel, Quinlyn A. Soltow, Mili Kapoor, Molly K. Moloney, Peter J. Webb, Michael Trzoss, Marc Sharp, Karen Joy Shaw
Chapter 11The Evolution of NNRTIs Leading to Doravirine (PIFELTRO®).
Abdellatif El Marrouni, Christopher S. Burgey
Chapter 12Exploiting Penicillin-Binding Protein-Mediated Inhibition of Cell Wall Biosynthesis for the Treatment of Bacterial Infections.
Bin Liu, Jodie Hamrick, Denis M. Daigle, Stephen M. Condon
Chapter 13Small-Molecule Therapeutics Targeting RNA.
Justin T. Ernst, Christian Nilewski, Peggy Thompson, Craig Stumpf
Chapter 14Recent Applications of Covalent Chemical Probes for Investigating Drug Off-Target Engagement.
Christopher W. am Ende, Jaimeen D. Majmudar, Ralph P. Robinson
Chapter 15Predicting Human Brain Exposure: Recent Advancements Integrating In Vitro, In Silico and Preclinical Data.
Nandini C. Patel
Chapter 16Design and Tactical Applications of Prodrugs to Enable Effective Drug Delivery.
Murugaiah A. M. Subbaiah, Nicholas A. Meanwell
Chapter 17Advances in the Development of Deubiquitinase (DUB) Inhibitors.
Jian Wu, Xu Wang, Kumar Suresh
Chapter 18Development of Small Molecules to Modulate the Activity of the ATP-Dependent ClpP Protease as a Novel Antibacterial and Anticancer Drug Target.
Funing Lin, Mark F. Mabanglo, Walid A. Houry, Robert A. Batey
Chapter 19Case History: DaurismoTM (Glasdegib), for the Treatment of Patients with Acute Meyloid Leukemia.
Nandini C. Patel, Michael J. Munchhof
Chapter 20Case History: Talzenna® (Talazoparib)—A Highly Potent, Orally Efficacious PARP Inhibitor for the Treatment of BRCA-Mutated, HER2-Negative Breast Cancer Patients.
Bing Wang, Yuqiao Shen, Leonard E. Post
Chapter 21New Chemical Entities Entering Phase III Trials in 2018.
Adam J. Schrier, Nathan E. Wright, David W. Lin, Vickie Tsui, Gregory T. Notte, Amy S. Lee
Chapter 22To Market, to Market—2018: Small Molecules.
Erika Araujo, Marie-Gabrielle Braun, Peter S. Dragovich, Antonella Converso, Philippe G. Nantermet, Anthony J. Roecker, T. G. Murali Dhar, Pamela Haile, Anna Hurtley, J. Robert Merritt, Kevin M. Peese
Chapter 23To Market, to Market—2018: Biologics.
Catherine A. Bolger, Suzana A. Kahn, Daša Lipovšek, William Mallet, James Wieler